Company inks deals with Lazeo and Transform,
two of Europe’s largest aesthetic and weight loss groups
Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to
ending obesity, today announced further expansion of its Virtual
Care Suite (VCS) digital platform with new commercial agreements
signed with Lazeo, France's largest aesthetic and weight loss
clinic chain, and Transform, UK's largest aesthetic and weight loss
clinic chain.
After recently expanding its commercial agreement with Weight
Doctors®—Germany’s leading group of private clinics and centers for
weight loss—Allurion believes that the accelerated expansion of VCS
through key partnerships underscores the growing number of
opportunities for the digital platform since launching Coach
Iris—Allurion’s 24/7 AI-powered weight loss coach—in October
2023.
The Allurion Virtual Care Suite is a comprehensive set of tools
designed to power any weight loss practice: in an Allurion study,
87% of providers who use the VCS report increased patient
accountability, 88% report increased efficiencies in their
practice, and 82% report increased patient engagement. Clinics with
the highest VCS usage rate achieve on average 11% additional weight
loss, with over 16% additional patients reaching their goals. With
the launch of Coach Iris, the VCS now provides 24/7 coaching and
guidance to patients across multiple modalities of care, including
anti-obesity medications, devices, and bariatric surgery.
In France, Lazeo successfully introduced the VCS to their
Allurion Program patients and as part of Nutricare by Lazeo—a
dietitian-supervised nutrition program spanning 3, 6 or 12 months,
depending on the needs of the patient—to enhance patient
engagement, streamline workflow and improve patient outcomes.
Bernard Sillam, founder & CEO of Lazeo, expressed enthusiasm
about the partnership, stating: "Allurion's Virtual Care Suite has
been a game-changer for Lazeo. The integration of VCS has enabled
us to introduce innovative nutrition programs with and without the
balloon, powered by VCS and Coach Iris, thereby providing our
patients with a comprehensive and personalized weight loss journey.
Making Allurion’s platform available to our patients is in line
with our desire to offer them the latest, most cutting-edge
innovations. It is also an opportunity for us to integrate
generative artificial intelligence into the world of aesthetic
medicine."
In the UK, Transform introduced VCS in order to elevate the
experience for their Allurion Program and bariatric surgery
patients, demonstrating a commitment to cutting-edge patient
care.
Tony Veverka, CEO of Transform Healthcare, highlighted
the significance of the collaboration, saying, "Transform is
excited to launch the VCS in 2024 as an additional support to our
Weight Loss+ programme. This partnership aligns perfectly with our
goal of enhancing the experience for our Allurion Program and
surgical patients. Making the weight loss journey less complex,
easier, with an ever-increasing likelihood of a desired result is
at the heart of what we do, and Coach Iris brings an added layer of
“always-on” support and advice, ensuring our patients receive
personalized care that meets the highest standards."
Coach Iris, Allurion's AI-powered weight loss coach, continues
to evolve, offering increasingly comprehensive support across all
treatment types. The latest update includes enhanced capabilities
tailored for bariatric surgery patients, that the company believes
will result in significantly improved responses and support for
these patients.
Dr. Shantanu Gaur, Founder and CEO of Allurion, stated, "Our
growing partnerships with industry leaders like Lazeo and Transform
demonstrate the power and versatility of the Virtual Care Suite. As
we continue to improve Coach Iris, we are confident in our ability
to scale our VCS business while providing unmatched support to
patients and empowering healthcare providers on the frontlines of
obesity care."
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight-loss platform that combines the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less gastric
balloon for weight loss, the Allurion Virtual Care Suite, including
the Allurion Mobile App for consumers, Allurion Insights for
healthcare providers featuring the Coach Iris AI Platform, and the
Allurion Connected Scale. The Allurion Virtual Care Suite is also
available to providers separately from the Allurion Program to help
customize, monitor, and manage weight-loss therapy for patients
regardless of their treatment plan, whether it is gastric balloon,
surgical, medical or nutritional. The Allurion Gastric Balloon is
an investigational device in the United States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
About Lazeo
With over 150 centers in France, Lazeo is the leading provider
of aesthetic medicine and laser hair removal. Lazeo uses its
know-how, medical expertise and 30 years of experience to put
advances in aesthetic medicine at the service of its patients:
concrete results without the need for major or invasive surgical
procedures.
To find out more: www.lazeo.com
About Transform
Transform is an innovative healthcare business, and the UK’s
leading provider of cosmetic surgery, weight loss surgery, general
surgery and vision correction. With its own state-of-the-art
hospitals, Transform provides unrivalled levels of personalised
care and world-class treatments, aligned with delivering results
that exceed expectations.
To find out more: https://www.transforminglives.co.uk/
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding Allurion’s expectations for, and
market acceptance of, Allurion’s Virtual Care Suite and the
Allurion Program in general, and Allurion’s ability to scale its
business and in particular for the VCS. Forward-looking statements
are predictions, projections and other statements about future
events that reflect the current beliefs and assumptions of
Allurion’s management based on information currently available to
them and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future results or developments to differ
materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Allurion to obtain regulatory approval for and successfully
commercialize the Allurion Program, (ii) the results of clinical
data from its studies, (iii) the evolution of the markets in which
Allurion competes, (iv) the ability of Allurion to defend its
intellectual property and satisfy regulatory requirements, (v) the
impact of the COVID-19 pandemic on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities,
including those for the VCS platform, and (vii) the risk of
economic downturns and a changing regulatory landscape in the
highly competitive industry in which Allurion operates. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of the proxy
statement/prospectus contained in Allurion’s Form 10-Q filed on
November 14, 2023, the company’s and other documents filed by
Allurion from time to time with the U.S. Securities and Exchange
Commission. These filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Allurion assumes no obligation and
does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. Allurion does not give any assurance that it will
achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117194759/en/
US Media Brian Ruby ICR (203) 682-8268
brian.ruby@icrinc.com
Global Media Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investor Mike Cavanaugh, Investor Relations ICR Westwicke
(617) 877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
過去 株価チャート
から 11 2024 まで 12 2024
Allurion Technologies (NYSE:ALUR)
過去 株価チャート
から 12 2023 まで 12 2024
